Skip to Content
Merck
  • Suppression of phospho-p85α-GTP-Rac1 lipid raft interaction by bichalcone analog attenuates cancer cell invasion.

Suppression of phospho-p85α-GTP-Rac1 lipid raft interaction by bichalcone analog attenuates cancer cell invasion.

Molecular carcinogenesis (2016-01-13)
Hui-Li Lu, Shih-Shun Chen, Wen-Tung Hsu, Yao-Cheng Lu, Chuan-Chun Lee, Tian-Shung Wu, Meng-Liang Lin
ABSTRACT

The p85α subunit of phosphatidylinositol 3-kinase (PI3K) acts as a key regulator of cell proliferation and motility, which mediates signals that confer chemoresistance to many human cancer cells. Using small interfering RNAs against matrix metalloproteinase-2 (MMP-2) and the MMP-2 promoter-driven luciferase assay, we showed that the new synthetic bichalcone analog TSWU-CD4 inhibits the invasion of human cancer cells by down-regulating MMP-2 expression. Treatment with TSWU-CD4 inhibited MMP-2 expression and cell invasion, which were restored by ectopic wild type (wt) p85α or a constitutively active form of MAPK kinase 3 (CA MKK3), CA MKK6, or CA p38α mitogen-activated protein kinase (MAPK). The attenuated formation of lipid raft-associated phospho (p)-p85α-GTP-Rac1 complexes, protein kinase B (Akt) Ser 473 phosphorylation, and cell invasion by TSWU-CD4 was reversed by overexpression of wt p85α or the p85α Brc-homology (BH) domain. The ectopic expression of CA Rac1

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
N-p-Tosyl-L-phenylalanine chloromethyl ketone, ≥97% (TLC), powder
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
SP600125, ≥98% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting human MMP2
Sigma-Aldrich
MISSION® esiRNA, targeting human MMP9